ESC Congress 2022 (Photo by Kyle LaHucik)
#ESC22: 89bio heads toward PhIII in severe hypertriglyceridemia, a field left behind by Pfizer earlier this year
BARCELONA — Two months after revealing the topline data — and quickly going to the market for a capital infusion of $95 million — 89bio is now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
